Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05267535 · ClinicalTrials.gov registry record · Phase 2
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by Neurim Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
- 20
- Study locations
NCT05267535 is a Phase 2 study of Alzheimers Disease that is active but no longer recruiting, run by Neurim Pharmaceuticals. The registered enrollment target is 225 participants, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT05267535, a Phase 2 study of Alzheimers Disease, is active but no longer recruiting, sponsored by Neurim Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
- 20
- Study locations
Study Summary
Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are 2:107,510,000-107,540,000 polymorphism non-carriers with the primary objective to compare the effect of piromelatine to that of placebo on the AD Assessment Scale cognitive subscale (ADAS-cog14) at Week 26 of double-blind treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Piromelatine 20 mg
Study Locations (20)
Florida
- Linfritz Research Institute Inc. - Coral Gables
- Finlay Medical Research Corp. - Greenacres City
- Velocity Clinical Research, Inc - Hallandale
- K2 Medical Research The Villages - Lady Lake
- Verus Clinical research Corp - Miami
- BioMed Research Institute, Inc. - Miami
- CCM Clinical Research Group, LLC - Miami
- Advance Medical Research Center - Miami
- Allied Biomedical Research Institute (Clinical Trials) - Miami
- Vitae Research Center LLC. - Miami
- Stein Gerontological Institute, Inc. - Miami
- Miami Dade Medical Research Institute - Miami
- K2 Medical Research Winter Garden - Ocoee
- Interspond, LLC, - Orlando
California
- ATP Clinical Research - Costa Mesa
- Collaborative Neuroscience Research, LLC - Long Beach
- Asclepes Research Centers, P.C. Dba Alliance Research - Long Beach
- Pacific Research Network, LLC - San Diego
- RAA Apex Acquisition LLC DBA Syrentis Clinical Research - Santa Ana
Colorado
- The Mile High Research Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2022-05-12 |
| Est. Completion | 2025-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05267535
The ClinicalTrials.gov registry entry for NCT05267535 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (94% lower). The listed sponsor is Neurim Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05267535 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05267535 about?
NCT05267535 is a clinical study titled "Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease". Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are 2:107,510,000-107,540,000 polymorphism non-carriers with the primary objective to compare the effect of piromelatine to that of placebo on the AD Asses...
What is the current status of trial NCT05267535?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2022-05-12. Estimated completion is 2025-06.
What conditions does trial NCT05267535 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT05267535?
The interventions under investigation include: Placebo (DRUG), Piromelatine 20 mg (DRUG).
Who is sponsoring clinical trial NCT05267535?
This trial is sponsored by Neurim Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05267535 being conducted?
This trial has 20 study locations across California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.